Association of inflammation with glycemic control, insulin sensitivity, and beta-cell function in diabetic cats
Sabine Thalmeier1, Tereza Jaresova1, Ruth Gostelow2
1Small Animal Clinic, Internal Medicine, Justus-Liebig-University Giessen, Giessen, Germany.
Background:
There is an association between inflammation and glycemic control (GC), β-cell function (BCF), and insulin resistance (IR) in humans.
Hypothesis/Objectives:
To assess the association between acute phase reaction (APR) (indicating inflammation) and markers reflecting GC, BCF, IR, and the presence of comorbidities in diabetic cats.
Animals:
Serial serum samples from 69 diabetic cats, treated with long-acting insulin or long-acting insulin in combination with long-acting exenatide at a single study center from 2013 to 2018.
Methods:
In this retrospective study, acute phase proteins (APPs), serum amyloid A (SAA), α-1-acid glycoprotein (AGP), and haptoglobin (Hp) were measured. Quality of GC (based on fructosamine), BCF test results, IR measures, and the presence of comorbidities from 4 study visits (enrolment, months 1, 3, and 6) were included. Mixed effects modeling, principal component analysis, and χ2-test were used to assess associations.
Results:
Glycemic control, BCF, and IR improved over the study period. There was no association between the quality of GC and the concentration of any of the 3 APPs (SAA: P = .35; AGP: P = .59; Hp: P = .1), nor an association between APR and fructosamine concentration (P = .35), BCF or IR measures (all P > .05). β-cell function was strongly associated with GC (P < .001; odds ratio 0.27; 95% CI, 0.14-0.51), but IR or APR were not. Acute phase reaction was not associated with comorbidities (P = .13).
Conclusions And Clinical Importance:
Our data suggest that inflammatory state does not predict poor GC assessed by serum fructosamine concentration in diabetic cats, but BCF is an important determinant of GC.
